Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.

NCT ID: NCT00124059

Last Updated: 2015-10-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-03-31
• Study Completion Date: 2005-10-31

Brief Summary

The purpose of this study is to determine whether seroquel is effective in the treatment of type A and type B alcohol dependence.

Detailed Description

The purpose of this study is to obtain preliminary data regarding the safety, efficacy and tolerability of quetiapine [Seroquel (SQL)] in treating Type A vs B alcohol dependent outpatients seeking treatment.

Conditions

Alcoholism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Type A SERO

Group Type: EXPERIMENTAL

Seroquel

Intervention Type: DRUG

400mg/day quetiapine

Type B SERO

Group Type: EXPERIMENTAL

Seroquel

Intervention Type: DRUG

400mg/day quetiapine

Type A PLA

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

400mg/day placebo

Type B PLA

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

400mg/day placebo

Interventions

Seroquel

400mg/day quetiapine

Intervention Type: DRUG

Placebo

400mg/day placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female and 18-65 years old.

2. Has a DSM-IV diagnosis of current alcohol dependence.

3. Has either Type A or Type B alcohol dependence, determined by cut-off scores for drinking amounts per day (TLFB), depression symptoms (Hamilton Depression Rating Scale--HDRS; Hamilton, 1967), and number of childhood antisocial personality symptoms. These three variables were selected based on recently published data on alcohol subtyping by Pettinati et al., 2000b).

4. Meets the following drinking criteria, measured by TLFB: a. drink within 30 days of starting pharmacotherapy treatment, b. reports a minimum of 48 standard alcoholic drinks (avg 12 drinks/wk) in a consecutive 30-day period over the 90-day period prior to starting pharmacotherapy (i.e., a minimum of 40% days drinking), and c. has 2 or more days of heavy drinking (defined as 5 or more drinks per day in males and 4 or more drinks per day in females) in this same pre-treatment period. [Note: To be a subject in the study, the patient must have been drinking enough in the 90 days before the trial so that a baseline exists in order to then measure reductions in drinking during the trial.]

5. Prior to starting pharmacotherapy, scores below 8 on the Clinical Institutes Withdrawal Assessment for Alcohol (CIWA; Shaw et al, 1981), and has at least 3 consecutive days of abstinence, as determined by subject report, breathalyzer measures, and a collateral report.

6. Speaks, understands and prints in English.

7. Gives written informed consent.

Exclusion Criteria

1. Has evidence of dependence on a substance other than alcohol (except nicotine), test positive on the urine drug screen (with the exception of THC) in the screening week (only one repeat testing permitted), or require inpatient detoxification for any substance.

2. Has hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at least 4.5 times normal after the required 3 days of abstinence, or elevated bilirubin (>1.3).

3. Patients with hepatocellular disease as evidenced by AST or ALT levels at least 2 times normal who test positive on a screening test for hepatitis A, B or C.

4. Meets diagnostic criteria for a current unstable or serious psychiatric or medical illness. For example, bipolar affective disorder, schizophrenia or any other psychotic disorder, or organic mental disorder; has serious heart, lung, kidney, immune system, GI tract (ulcerative colitis, regional enteritis, or gastrointestinal bleeding) disease.

5. Has taken any psychotropic medications (or disulfiram) regularly within the last 2 weeks or needs immediate treatment with a psychotropic medication (with the exception of detoxification medications or benadryl used sparingly for sleep);

6. Tests positive on a pregnancy test, is contemplating pregnancy in the next 12 months, is nursing, or is not using an effective contraceptive method if the S is of child-bearing potential.

7. Has known hypersensitivity to antipsychotics.

8. Has participated in any investigational drug trial within 30 days prior to the study.

9. History of seizures including alcohol withdrawal seizures.

10. History of head trauma.

11. Family history of seizures.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Helen M Pettinati, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania Treatment Research Center

Locations

University of Pennsylvania Treatment Research Center

Philadelphia, Pennsylvania, United States

Countries

United States

References

Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O'Brien CP. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol. 2007 Aug;27(4):344-51. doi: 10.1097/JCP.0b013e3180ca86e5.

Reference Type: RESULT

PMID: 17632217 (View on PubMed)

Other Identifiers

706689

Identifier Type: -

Identifier Source: org_study_id